Zivo Bioscience, Inc.
ZIVO
$17.76
$1.7611.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 157.20K | 79.00K | 59.30K | 63.40K | 27.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 157.20K | 79.00K | 59.30K | 63.40K | 27.70K |
| Cost of Revenue | 108.30K | 53.00K | 38.60K | 39.30K | 16.10K |
| Gross Profit | 49.00K | 26.10K | 20.70K | 24.00K | 11.50K |
| SG&A Expenses | 10.28M | 10.48M | 9.90M | 5.30M | 5.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.52M | 13.74M | 13.03M | 6.63M | 7.29M |
| Operating Income | -13.36M | -13.66M | -12.97M | -6.57M | -7.26M |
| Income Before Tax | -13.38M | -13.69M | -13.25M | -7.08M | -7.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.38 | -13.69 | -13.25 | -7.08 | -7.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.38M | -13.69M | -13.25M | -7.08M | -7.78M |
| EBIT | -13.36M | -13.66M | -12.97M | -6.57M | -7.26M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -4.36 | -4.90 | -5.29 | -3.83 | -4.62 |
| Normalized Basic EPS | -2.73 | -3.06 | -3.30 | -2.39 | -2.89 |
| EPS Diluted | -4.36 | -4.90 | -5.29 | -3.83 | -4.62 |
| Normalized Diluted EPS | -2.73 | -3.06 | -3.30 | -2.39 | -2.89 |
| Average Basic Shares Outstanding | 12.66M | 11.05M | 9.37M | 7.98M | 6.80M |
| Average Diluted Shares Outstanding | 12.66M | 11.05M | 9.37M | 7.98M | 6.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |